US6951271005
© Globe Newswire
26.11.2025
PCRX
LISTED
NASDAQ
Pacira BioSciences Files EXPAREL® Patent Infringement Lawsuits Against The WhiteOak Group and Qilu Pharmaceutical
News Preview
-- Lawsuit triggers 30-month stay under the Hatch Waxman Act -- BRISBANE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it has filed a patent infringement lawsuit in t...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.11.2025
PCRX
LISTED
NASDAQ
Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences
News Preview
BRISBANE, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will participate in an analyst-led fireside chat at the following two healthcare conferences:...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.10.2025
PCRX
LISTED
NASDAQ
Pacira to Report Third Quarter 2025 Financial Results on Thursday November 6, 2025
News Preview
BRISBANE, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will report its third quarter financial results after the close of the U.S. markets on Thursday November 6,...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© Globe Newswire
27.10.2025
PCRX
LISTED
NASDAQ
Pacira BioSciences Notified of Abbreviated New Drug Application Filing from Qilu Pharmaceutical (Hainan) Co., Ltd. for EXPAREL®
News Preview
BRISBANE, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients today reported it has received a Paragraph IV Certification Notice Letter (PIV Notice) from Qilu Pharmaceutical (Hainan) Co., Ltd., a...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
23.10.2025
PCRX
LISTED
NASDAQ
Pacira BioSciences to Present New Data from Three Real-World Studies with EXPAREL®
News Preview
-- Findings Presented at AMCP Nexus 2025 Annual Meeting -- BRISBANE, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced real-world evidence evaluating the clinical effectiveness and econo...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.10.2025
PCRX
LISTED
NASDAQ
Pacira BioSciences Notified of Abbreviated New Drug Application Filing from The WhiteOak Group for EXPAREL®
News Preview
BRISBANE, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients today reported it has received a Paragraph IV Certification Notice Letter (PIV Notice) from The WhiteOak Group, a subsidiary of a sma...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.10.2025
PCRX
LISTED
NASDAQ
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
BRISBANE, Calif., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards on October 2, 2025 to 15 new employees under Pacira’s Amended and Restated 2014 Inducement P...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.09.2025
PCRX
LISTED
NASDAQ
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
BRISBANE, Calif., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards on September 3, 2025 to nine new employees under Pacira’s Amended and Restated 2014 Inducem...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.07.2025
PCRX
LISTED
NASDAQ
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
BRISBANE, Calif., July 03, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards on July 2, 2025 to seven new employees under Pacira’s Amended and Restated 2014 Inducement P...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.06.2025
PCRX
LISTED
NASDAQ
Pacira BioSciences Debuts Inspiring New Film Highlighting One Patient’s Journey to Pain Relief and Innovation in Care at BIO 2025
News Preview
- Produced for Pacira by BBC StoryWorks Commercial Productions, The Next Frontier: Mark & Leah’s Story Highlights the Impact of Non-Opioid Solutions -...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.06.2025
PCRX
LISTED
NASDAQ
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
BRISBANE, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards on June 3, 2025 to 19 new employees under Pacira’s Amended and Restated 2014 Inducement Plan...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.05.2025
PCRX
LISTED
NASDAQ
Pacira BioSciences to Present New Data on Clinical Immunogenicity of Intra-Articular PCRX-201 and Its Implications for Dosing Strategy in Knee Osteoarthritis
News Preview
Data will be featured at the ASGCT 28th Annual Meeting Data will be featured at the ASGCT 28th Annual Meeting...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© PR Newswire
21.04.2025
PCRX
LISTED
NASDAQ
DOMA Perpetual Supports Pacira's New $300 Million Share Repurchase Authorization as a Meaningful Step to Enhance Value for Shareholders
News Preview
DOMA Perpetual Believes Pacira's Stock Is Undervalued, Presenting an Opportunity to Execute the Largest Buyback in the Company's History
MIAMI, April 21, 2025 /PRNewswire/ -- DOMA Perpetual Capital Management LLC (collectively with its affiliates, "DOMA Perpetual" or "We") is a fundamentals-based, value-oriented asset management firm which benefi...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.04.2025
PCRX
LISTED
NASDAQ
Pacira BioSciences Reaffirms Commitment to Enhancing Value for All Shareholders
News Preview
-- $300 million aggregate share repurchase authorization-- -- Reinforces confidence in 5x30 plan –...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.04.2025
PCRX
LISTED
NASDAQ
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
BRISBANE, Calif., April 11, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced the granting of inducement awards on April 2, 2025 to 18 new employees under Pacira’s Amended and Restated 2014 Inducement Plan (the “Inducement Plan”) as a mat...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.04.2025
PCRX
LISTED
NASDAQ
Pacira BioSciences Announces Settlement of U.S. Patent Litigation for EXPAREL
News Preview
-- Fresenius Kabi licensed to sell volume-limited amounts of generic bupivacaine liposome injectable suspension in the U.S. no earlier than a confidential date in 2030 -- -- Fresenius also licensed to sell generic bupivacaine liposome injectable suspension in the U.S. without volume limitations beginning in 2039 --...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.03.2025
PCRX
LISTED
NASDAQ
Pacira BioSciences Confirms Receipt of Director Nominations from DOMA Perpetual
News Preview
-- No Shareholder Action Required at This Time -- PARSIPPANY, N.J., March 14, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today confirmed that DOMA Perpetual Capital Management LLC (“DOMA”) has nominated...
Themefolio
Profiler
Peergroup
© PR Newswire
14.03.2025
PCRX
LISTED
NASDAQ
DOMA Perpetual Nominates Three Highly Qualified Candidates for the Board of Pacira BioSciences
News Preview
Pacira's Stock is Down 76% Over the Last Decade, While the Board and Management Have Enriched Themselves at a Cost of Half a Billion Dollars, Roughly 50% of the Current Market Cap
Under CEO and Board Member Frank Lee, the Stock Price Has Declined 33%; He is Pushing for Higher Compensation Packages for Management While Burdening Shareholders with...
Themefolio
Profiler
Peergroup
© BusinessWire
11.03.2025
PCRX
LISTED
NASDAQ
PACIRA BIOSCIENCES 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuits Against Pacira BioSciences, Inc. - PCRX
News Preview
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until March 14, 2025 to file lead plaintiff applications in a securities class action lawsuit against Pacira BioSciences, Inc. (the “Company”) (NasdaqGS: PCRX), if they purchased the Company’s securiti...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.03.2025
PCRX
LISTED
NASDAQ
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
PARSIPPANY, N.J., March 06, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced the granting of inducement awards on March 4, 2025 to six new employees under Pacira’s Amended and Restated 2014 Inducement Plan (the “Inducement Plan”) as a ma...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.02.2025
PCRX
LISTED
NASDAQ
Pacira BioSciences Acquires Remaining Equity Stake of GQ Bio
News Preview
-- Advances Pacira’s “5x30” path to becoming an innovative biopharmaceutical organization -- -- Adds novel, high-capacity, local-delivery platform for the development of genetic medicines with disease-modifying potential for prevalent musculoskeletal diseases with significant unmet needs --...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.02.2025
PCRX
LISTED
NASDAQ
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
PARSIPPANY, N.J., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards on February 4, 2025 to 15 new employees under Pacira’s Amended and Restated 2014 Inducement...
Themefolio
Profiler
Peergroup
© BusinessWire
26.01.2025
PCRX
LISTED
NASDAQ
PCRX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Pacira BioSciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
News Preview
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Pacira BioSciences, Inc. (“Pacira” or “the Company”) (NASDAQ: PCRX) and certain of its officers.
Class Definition
This lawsuit seeks to recover damages against Defendants for alle...
Themefolio
Profiler
Peergroup
© BusinessWire
17.01.2025
PCRX
LISTED
NASDAQ
PCRX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Pacira BioSciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
News Preview
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Pacira BioSciences, Inc. (“Pacira” or “the Company”) (NASDAQ: PCRX) and certain of its officers.
Class Definition
This lawsuit seeks to recover damages against Defendants for alle...
Themefolio
Profiler
Peergroup
© BusinessWire
15.01.2025
PCRX
LISTED
NASDAQ
PACIRA BIOSCIENCES SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Pacira BioSciences, Inc. - PCRX
News Preview
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until March 14, 2025 to file lead plaintiff applications in a securities class action lawsuit against Pacira BioSciences, Inc. (the “Company”) (NasdaqGS: PCRX), if they purchased the Company’s securities b...
Themefolio
Profiler
Peergroup
© BusinessWire
14.01.2025
PCRX
LISTED
NASDAQ
PCRX Investors Have Opportunity to Lead Pacira BioSciences, Inc. Securities Fraud Lawsuit with the Schall Law Firm
News Preview
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Pacira BioSciences, Inc. (“Pacira” or “the Company”) (NASDAQ: PCRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission....
Themefolio
Profiler
Peergroup
© BusinessWire
14.01.2025
PCRX
LISTED
NASDAQ
Rosen Law Firm Urges Pacira BioSciences, Inc. (NASDAQ: PCRX) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
News Preview
Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of all purchasers or acquirers of securities of Pacira BioSciences, Inc. (NASDAQ: PCRX) between August 2, 2023 and August 8, 2024, both dates inclusive (the “Class Period”). Pacira is a pharmaceutical company.
For more information, subm...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.12.2024
PCRX
LISTED
NASDAQ
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
News Preview
PARSIPPANY, N.J., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced the granting of inducement awards on December 3, 2024 to four new employees under Pacira’s Amended and Restated 2014 Inducement Plan as a material inducement to...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.11.2024
PCRX
LISTED
NASDAQ
Pacira Announces 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee
News Preview
-- Poster to be presented at ACR Convergence annual meeting -- -- Poster to be presented at ACR Convergence annual meeting --...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.10.2024
PCRX
LISTED
NASDAQ
Pacira to Report Third Quarter 2024 Financial Results on Wednesday November 6, 2024
News Preview
PARSIPPANY, N.J., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its third quarter financial results after the close of the U.S. markets on Wednesday November 6, 2024. Following the release, the company will host a live conference call and webcast at 4:30 p.m. ET....
Themefolio
Profiler
Peergroup
© Globe Newswire
21.10.2024
PCRX
LISTED
NASDAQ
Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer
News Preview
Seasoned Executive Brings More Than 25 Years of Global Financial and Operational Biopharmaceutical Leadership Experience Seasoned Executive Brings More Than 25 Years of Global Financial and Operational Biopharmaceutical Leadership Experience...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.10.2024
PCRX
LISTED
NASDAQ
Pacira BioSciences Announces New Product-Specific J-Code for EXPAREL Effective January 1, 2025
News Preview
-- New J-code issued by the Centers for Medicare and Medicaid Services expected to standardize and streamline billing and reimbursement -- TAMPA, Fla., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced that the Centers for Medica...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.09.2024
PCRX
LISTED
NASDAQ
Pacira Announces the Presentation of 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee
News Preview
-- Poster to be presented at ACR Convergence annual meeting -- TAMPA, Fla., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced the upcoming presentation of new data in support of its gene therapy candidate, PCRX-201 (enekinragene...
Themefolio
Profiler
Peergroup
© PR Newswire
25.09.2024
PCRX
LISTED
NASDAQ
DOMA Perpetual Sends Letter to Board of Directors of Pacira Biosciences to Immediately Accelerate and Increase its Share Buyback Program to Enhance Return to Shareholders
News Preview
Believes Pacira's Cash Balance of $400 million, Roughly 59% of its Market Capitalization, is Grossly Inefficient.
Emphasizes the Current Stock Price Offers an Extraordinary Opportunity to Create Meaningful Return for Shareholders
MIAMI, Sept. 25, 2024 /PRNewswire/ -- DOMA Perpetual Capital Management LLC today sent a letter to the Board of Direct...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.08.2024
PCRX
LISTED
NASDAQ
Pacira BioSciences Comments on Ruling on EXPAREL Patent Litigation from U.S. District Court for the District of New Jersey
News Preview
TAMPA, Fla., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced that the U.S. District Court for the District of New Jersey has found that the company’s U.S. Patent No. 11,033,495 (the ‘495 patent) is not...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.07.2024
PCRX
LISTED
NASDAQ
Centers for Medicare and Medicaid Propose New Reimbursement for EXPAREL in All Outpatient Surgical Environments Beginning January 1, 2025
News Preview
-- Proposed Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment System Rule extends separate payment from ambulatory surgical centers to include the hospital outpatient environment –...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.05.2024
PCRX
LISTED
NASDAQ
Pacira BioSciences to Participate in Fireside Chat at the 2024 Jefferies Global Healthcare Conference
News Preview
TAMPA, Fla., May 30, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the 2024 Jefferies Global Healthcare Conference at 11:00 AM ET on Thursday, June 6, 2024 in New York. Live audio of the event can be accessed by visiting the “Events” page of the company...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
